Arcellx Inc (ACLX NASDAQ) stock market data APIs
$85.5984
3.85(4.5%)
as of November 3, 2025
Try our APIs with
free plan!
Arcellx Inc Financial Data Overview
Price chart is built with
Anychart
Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; ARC-SparX programs in Phase 1 trials; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, the company focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Prev. Close
85.5984
Open
89.4512
High
93.032
Low
84.0001
52 wk Range
47.8601-107.37
Market Cap
5 005 M
Shares Outstanding
55 459 K
Revenue
56 979 K
EPS
-0.94
Beta
0.307
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Arcellx Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Arcellx Inc data using free add-ons & libraries
Get Arcellx Inc Fundamental Data
Arcellx Inc Fundamental data includes:
- Net Revenue: 56 979 K
- EBITDA: -208 075 008
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-07
- EPS/Forecast: -1.02
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Arcellx Inc News
New
Arcellx, Inc. (ACLX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Arcellx, Inc. (ACLX) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended September 2025. This widely-known consensus outlook giv...
CAR T-cell Therapy Market Forecasts Indicate Strong Growth Trajectory in the 7MM During the Forecast Period (2025-2034) | DelveInsight
The dynamics of the CAR T-cell therapy market are anticipated to change due to the extensive R&D activities, an increase in investment for research and development of the new CAR T-cell therapy, such ...
Why Arcellx (ACLX) Is Up 7.5% After Insider Sales and Optimism on CAR-T Regulatory Outlook
In early October 2025, Arcellx executives sold shares under pre-arranged trading plans as analysts highlighted improved regulatory prospects for Arcellx’s lead CAR-T therapy targeting multiple myelo...
CAR T-Cell Therapy for Multiple Myeloma Market to Witness Upsurge in Growth by 2034 Owing to the Launch of Emerging Therapies | DelveInsight
DelveInsight Business Research LLP The dynamics of the CAR-T cell therapy market for multiple myeloma are anticipated to change due to extensive R&D activities, increased investment in research and d...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
